Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of D-1553 in KRAS G12C-mutated advanced or metastatic solid tumors
CTR20212920Phase 2Active
- Sponsor
- InventisBio
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by InventisBio. Started Feb 2022; status: active.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212920.